[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"burn-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:burn-pain":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100659028","phoenixin-and-pain-in-pediatric-burn-patients-100659028",false,"NCT07858409","Phoenixin and Pain in Pediatric Burn Patients","Evaluation of the Pain-Related Potential of Phoenixin as a Biomarker in Pediatric Burn Patients","Inclusion Criteria:\n\n* Inclusion Criteria:\n* Children younger than 18 years of age who have not entered puberty.\n* Both sexes are eligible.\n* Written informed consent for participation in the study obtained from a parent or legal guardian.\n* For the acute burn group: children with second-degree burns who are being followed in the burn intensive care unit.\n* For the chronic burn group: a history of burn injury, with at least three months elapsed since the burn.\n* For the control group: no history of burn injury and no acute pain at the time of assessment.\n\nExclusion Criteria:\n\n* Neurological, endocrine, or active systemic inflammatory disease that may affect phoenixin (PNX) levels or pain assessment.\n* Having entered puberty.\n* Inability to obtain the biological samples required for the study.\n* Lack of written informed consent from a parent or legal guardian.",true,"ALL","1 Month","18 Years",{"count":21,"type":22},87,"ESTIMATED","OBSERVATIONAL","This prospective, controlled, observational study aims to investigate the relationship between phoenixin (PNX) levels and pain in pediatric burn patients. A total of 87 prepubertal children under 18 years of age will be included and evaluated in three independent groups: 29 children with second-degree burns in the acute burn period and experiencing pain at the time of assessment, 29 children with a history of burn injury at least three months previously who have completed the acute burn and procedural pain period, and 29 age-similar healthy controls without a history of burns or acute pain.\n\nBlood and urine samples will be collected from all participants, and PNX levels will be measured using an enzyme-linked immunosorbent assay (ELISA). Pain intensity will be assessed using age-appropriate validated pain assessment tools, including the Face, Legs, Activity, Cry, Consolability (FLACC) scale and the Visual Analog Scale (VAS), as appropriate. In the burn groups, burn characteristics, including total body surface area (TBSA), will also be recorded.\n\nThe study will compare blood and urine PNX levels among the acute burn, chronic burn, and healthy control groups and will evaluate the relationship between PNX levels and clinical pain intensity in children with acute burns. Secondary analyses will examine the relationships between blood and urine PNX levels and their associations with TBSA and demographic and clinical characteristics. The findings are expected to provide preliminary clinical data on the potential role of PNX as a pain-related biological marker in pediatric burn patients.",[26,27,28,29],"Children","Acute Pain","Burn Pain","Burn Degree Second",[31,32,33,28,34],"Phoenixin","Pediatric Burns","Pain Biomarker","PNX","NOT_YET_RECRUITING","2026-09-29",{"date":38,"type":39},"2026-10-05","ACTUAL",{"date":41,"type":22},"2026-10-01",{"date":43,"type":22},"2027-10-01",{"name":45,"class":46},"Ankara City Hospital Bilkent","OTHER"]